专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20200348286A1 OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION 审中-公开
公开(公告)号：US20200348286A1
公开(公告)日：2020-11-05
申请号：US16933445
申请日：2020-07-20
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S , HOFFMANN-LA ROCHE INC.
发明人： Veronica Costa , Maj HEDTJÄRN , Marius Hoener , Ravi Jagasia , Mads Aaboe Jensen , Christoph Patsch , Lykke Pedersen , Søren Vestergaard Rasmussen
IPC分类号： G01N33/50 , C12N5/0797 , C12N15/11 , C12N15/113 , C12N5/0793 , C12N5/00 , C12N5/074
摘要： The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

2. 发明申请

US20200057052A1 OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION 审中-公开
公开(公告)号：US20200057052A1
公开(公告)日：2020-02-20
申请号：US16663024
申请日：2019-10-24
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S , HOFFMANN-LA ROCHE INC.
发明人： Veronica Costa , Maj Hedtjärn , Marius Hoener , Ravi Jagasia , Mads Aaboe Jensen , Christoph Patsch , Lykke Pedersen , Søren Vestergaard Rasmussen
IPC分类号： G01N33/50 , C12N5/0793 , C12N15/113 , C12N5/00 , C12N5/074 , C12N15/11 , C12N5/0797
摘要： The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

3. 发明授权

US10739332B2 Oligonucleotides for inducing paternal UBE3A expression 有权
公开(公告)号：US10739332B2
公开(公告)日：2020-08-11
申请号：US16388714
申请日：2019-04-18
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S , HOFFMANN-LA ROCHE INC.
发明人： Veronica Costa , Maj Hedtjärn , Marius Hoener , Ravi Jagasia , Mads Aaboe Jensen , Christoph Patsch , Lykke Pedersen , Søren Vestergaard Rasmussen
IPC分类号： A61K48/00 , C12N15/11 , C07H21/02 , C07H21/04 , G01N33/50 , C12N5/0797 , C12N15/113 , C12N5/0793 , C12N5/00 , C12N5/074
摘要： The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

4. 发明授权

US10494633B2 Oligonucleotides for inducing paternal UBE3A expression 有权
公开(公告)号：US10494633B2
公开(公告)日：2019-12-03
申请号：US15351113
申请日：2016-11-14
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S , HOFFMANN-LA ROCHE INC.
发明人： Veronica Costa , Maj Hedtjärn , Marius Hoener , Ravi Jagasia , Mads Aaboe Jensen , Christoph Patsch , Lykke Pedersen , Søren Vestergaard Rasmussen
IPC分类号： C12N15/11 , A61K48/00 , C07H21/02 , C12N15/113 , C12N5/0793 , C12N5/0797 , G01N33/50
CPC分类号： C12N15/1137 , C12N5/0619 , C12N5/0623 , C12N15/111 , C12N15/113 , G01N33/5014 , G01N33/5058 , C12N2310/11 , C12N2310/20 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/33 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2320/34 , C12N2500/38 , C12N2500/44 , C12N2501/01 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/13 , C12N2501/41 , C12N2501/60 , C12N2501/727 , C12N2501/999 , C12N2503/02 , C12N2506/45 , C12N2533/52
摘要： The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

5. 发明申请

US20190310244A1 OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION 审中-公开
公开(公告)号：US20190310244A1
公开(公告)日：2019-10-10
申请号：US16388714
申请日：2019-04-18
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S , HOFFMANN-LA ROCHE INC.
发明人： Veronica Costa , Maj HEDTJÄRN , Marius Hoener , Ravi Jagasia , Mads Aaboe Jensen , Christoph Patsch , Lykke Pedersen , Søren Vestergaard Rasmussen
IPC分类号： G01N33/50 , C12N5/074 , C12N15/11 , C12N5/00 , C12N15/113 , C12N5/0797 , C12N5/0793
摘要： The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

6. 发明申请

US20220146496A1 OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION 有权
公开(公告)号：US20220146496A1
公开(公告)日：2022-05-12
申请号：US17581089
申请日：2022-01-21
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S , HOFFMANN-LA ROCHE INC.
发明人： Veronica Costa , Maj HEDTJÄRN , Marius Hoener , Ravi Jagasia , Mads Aaboe Jensen , Christoph Patsch , Lykke Pedersen , Søren Vestergaard Rasmussen
IPC分类号： G01N33/50 , C12N5/0797 , C12N15/11 , C12N15/113 , C12N5/0793 , C12N5/00 , C12N5/074
摘要： The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

7. 发明授权

US10718753B2 Oligonucleotides for inducing paternal UBE3A expression 有权
公开(公告)号：US10718753B2
公开(公告)日：2020-07-21
申请号：US16663024
申请日：2019-10-24
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S , HOFFMANN-LA ROCHE INC.
发明人： Veronica Costa , Maj Hedtjärn , Marius Hoener , Ravi Jagasia , Mads Aaboe Jensen , Christoph Patsch , Lykke Pedersen , Søren Vestergaard Rasmussen
IPC分类号： A61K48/00 , C12N15/11 , C07H21/02 , C07H21/04 , G01N33/50 , C12N5/0797 , C12N15/113 , C12N5/0793 , C12N5/00 , C12N5/074
摘要： The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

8. 发明申请

US20170191064A1 OLIGONUCLEOTIDES FOR INDUCING PATERNAL UBE3A EXPRESSION 审中-公开
公开(公告)号：US20170191064A1
公开(公告)日：2017-07-06
申请号：US15351113
申请日：2016-11-14
申请人： ROCHE INNOVATION CENTER COPENHAGEN A/S , HOFFMANN-LA ROCHE INC.
发明人： Veronica Costa , Maj HEDTJÄRN , Marius Hoener , Ravi Jagasia , Mads Aaboe Jensen , Christoph Patsch , Lykke Pedersen , Søren Vestergaard Rasmussen
IPC分类号： C12N15/113
CPC分类号： G01N33/5014 , C12N5/0018 , C12N5/0619 , C12N5/0623 , C12N5/0696 , C12N15/11 , C12N15/111 , C12N15/113 , C12N15/1137 , C12N2310/11 , C12N2310/20 , C12N2310/315 , C12N2310/321 , C12N2310/322 , C12N2310/3231 , C12N2310/33 , C12N2310/3341 , C12N2310/341 , C12N2310/346 , C12N2310/351 , C12N2320/34 , C12N2500/38 , C12N2500/44 , C12N2501/01 , C12N2501/11 , C12N2501/115 , C12N2501/119 , C12N2501/13 , C12N2501/41 , C12N2501/60 , C12N2501/727 , C12N2501/999 , C12N2503/02 , C12N2506/45 , C12N2533/52 , G01N33/5058
摘要： The present invention relates to oligonucleotides that are capable of inducing expression of ubiquitin-protein ligase E3A (UBE3A) from the paternal allele in animal or human neurons. The oligonucleotides target the suppressor of the UBE3A paternal allele by hybridization to SNHG14 long non-coding RNA downstream of SNORD109B. The present invention further relates to pharmaceutical compositions and methods for treatment of Angelman syndrome.

9. 发明申请

US20160326150A1 N-PHENYL-LACTAM DERIVATIVES CAPABLE OF STIMULATING NEUROGENESIS AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISORDERS 有权
标题翻译：刺激神经细胞的N-PHENYL-LACTAM衍生物及其在治疗神经疾病中的应用
公开(公告)号：US20160326150A1
公开(公告)日：2016-11-10
申请号：US15213622
申请日：2016-07-19
申请人： Hoffmann-La Roche Inc.
发明人： Roland Jakob-Roetne , Juergen Wichmann , Jens-Uwe Peters , Ravi Jagasia
IPC分类号： C07D413/10 , C07D401/10 , C07D401/14 , C07D403/10
CPC分类号： C07D413/10 , C07D401/10 , C07D401/14 , C07D403/10
摘要： The present invention relates to compounds of the general formula I wherein Het, R1, R2, W and X are as defined herein. Compounds of formula I are useful for treating neuropsychiatric disorders.

10. 发明授权

US09440962B2 Benzisoxazoles 有权
标题翻译：苯并恶唑
公开(公告)号：US09440962B2
公开(公告)日：2016-09-13
申请号：US14602541
申请日：2015-01-22
申请人： Hoffmann-La Roche Inc.
发明人： Simona M. Ceccarelli , Ravi Jagasia , Roland Jakob-Roetne , Juergen Wichmann
IPC分类号： A61K31/41 , C07D413/14 , C07D413/04 , C07D231/12 , C07D401/04
CPC分类号： C07D413/14 , C07D231/12 , C07D401/04 , C07D413/04
摘要： The present invention relates to compounds of general formula wherein Ar1/Ar2 are phenyl or a 5 or 6-membered heteroaryl; R1/R2 is hydrogen, halogen, lower alkyl, CF3 or lower alkoxy; n,m are 1 or 2; or to a pharmaceutically acceptable acid addition salt, to a racemic mixture or to its corresponding enantiomer and/or optical isomers thereof, with the exception of the compound 2,1-benzisoxazole, 3-(4-chlorophenyl)-5-(1-phenyl-1H-pyrazol-5 -yl)-. The compounds may be used for the treatment of schizophrenia, obsessive-compulsive personality disorder, major depression, bipolar disorders, anxiety disorders, normal aging, epilepsy, retinal degeneration, traumatic brain injury, spinal cord injury, post-traumatic stress disorder, panic disorder, Parkinson's disease, dementia, Alzheimer's disease, mild cognitive impairment, chemotherapy-induced cognitive dysfunction, Down syndrome, autism spectrum disorders, hearing loss, tinnitus, spinocerebellar ataxia, amyotrophic lateral sclerosis, multiple sclerosis, Huntington's disease, stroke, radiation therapy, chronic stress, abuse of neuro-active drugs, such as alcohol, opiates, methamphetamine, phencyclidine and cocaine.
摘要翻译：这些化合物可用于治疗精神分裂症，强迫症人格障碍，重症抑郁症，双相障碍，焦虑症，正常老化，癫痫，视网膜变性，创伤性脑损伤，脊髓损伤，创伤后应激障碍，恐慌症，帕金森病，痴呆，阿尔茨海默病，轻度认知障碍，化疗诱导的认知功能障碍，唐氏综合征，自闭症谱系障碍，听力损失，耳鸣，脊髓小脑共济失调，肌萎缩性侧索硬化，多发性硬化，亨廷顿氏病，中风，放射治疗，慢性压力，滥用神经活性药物，如酒精，阿片剂，甲基苯丙胺，苯环利定和可卡因。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式